IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Human Journals
Review Article
April 2020 Vol.:18, Issue:1

A Review on Proton Pump Inhibitors

IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

RAKSHITH B K*[1], RAJESHWARI AG[1], SUDARSHAN BS

Department of Pharmaceutics, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B G Nagar-571448

Submission: 24 March 2020
Accepted: 31 March 2020
Published: 30 April 2020

Keywords: Proton pump inhibitors, adverse effects, antacids

ABSTRACT

Proton pump inhibitors (PPIs) are first introduced in 1989, among the most widely utilized medications worldwide, both in the ambulatory and inpatient clinical settings. Overall, PPIs are irreplaceable drugs in the management of acid-related diseases. However, PPI treatment – as any kind of drug therapy – is not without risk of adverse effects. The overall benefits of therapy and improvement in the quality of life significantly outweigh potential risks in most patients, but those without clear clinical indication are only exposed to the risks of PPI prescription.

HUMAN JOURNALS
www.ijppr.humanjournals.com

INTRODUCTION

Proton pump inhibitors (PPIs) are first introduced in 1989, among the most widely utilized medications worldwide, both in the ambulatory and inpatient clinical settings. The PPIs are currently approved by the US Food and Drug Administration for the management of a variety of gastrointestinal disorders including symptomatic peptic ulcer disease, gastroesophageal reflux disease, and nonulcer dyspepsia and also for the prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. PPIs inhibit gastric acid secretion, and the most commonly associated adverse effects include abdominal pain, diarrhea, and headache. Although PPIs have had an encouraging safety profile, recent studies regarding the long-term use of PPI s medications have identified potential adverse effects, including the risk of fractures, pneumonia, Clostridium difficile diarrhea, hypomagnesemia, vitamin B12 deficiency, chronic kidney disease.[2]

Drug interactions are vital and often ignored thought when prescribing any medication. The potential interaction between PPIs and antiplatelet representatives has been the subject of multiple studies. One of the more recent concerns with PPI is used in the progression of chronic kidney disease. There is also some literature signifying that PPIs contribute to the growth of various micronutrient lacks.[3]

The economic problem associated with the use of PPIs in the overall population, concerns continue to surface about their use and potential difficulties such as bone fracture, dementia, cardiac event, renal disease, or infection. As the number of intelligence and press coverage related to the epidemiologic studies observing at the risk of PPIs increases, thoughts about their potential hazards are a weekly if not daily amount in otolaryngology outpatient clinics. The neutral of this review is to summarize the potential risks related to PPI use as a source for decision-making and patient therapy.[4]

Structure of the Gastric H^+, K^+-ATPase :

- The gastric H＋, K＋-ATPase is an α, β-heterodimeric enzyme. The α subunit, with a molecular mass of about 100 kDa, has the catalytic site and the β subunit, with peptide mass of 35 kDa, is strongly but non-covalently associated with the α subunit.

- The structure of gastric H＋, K＋-ATPase. The gastric H＋, K＋-ATPase α subunit has 3 lobes, N (ATP binding), P (phosphorylation), and A (activation) domains in the cytoplasmic domain, and 3 transmembrane segments in the membrane domain.

- The gastric β subunit has a short cytoplasmic region, 1 transmembrane segment, and a heavily glycosylated extracellular region. [5]

POTENTIAL ADVERSE EFFECTS OF PPI USE

➢ Loss of Bone Density and Rupture Hazard Although the exact device by which PPIs could cause bone fracture is unclear, two hypotheses include interference with the immersion of calcium salts and inhibition of bone remodeling.

➢ The first hypothesis proposes that hypochlorhydria may delay with calcium salts absorption, thus leading to secondary hyperparathyroidism and following bone resorption to uphold calcium levels. However, some studies have demonstrated that there may not be a meaningful impact of acid suppression on calcium absorption.

➢ The second hypothesis proposes a straight inhibition of bone-specific proton pump associated with osteoclasts, which outcomes in disruption of bone remodeling causing improved bone fragility without detectable modification in bone mineral density (BMD).[6]

Hypomagnesemia;

➢ As a chief electrolyte in the body, a deficiency in magnesium has been related to cardiovascular and noncardiovascular mortality. Severe hypomagnesemia can pose significant detrimental special effects such as arrhythmias, muscle weakness, tetany, or convulsions.

➢ Hypomagnesemia with PPI use is likely clarified by an increased renal loss and decreased immersion in the gastrointestinal tract because of interference with the Melastatin 6 (TRMP6) and TRMP7 active transporter. In their meta-analysis of three cohort educations, cross-sectional studies, and a case-control study on hypomagnesemia associated with PPI use, Cheungpasitporn et al. demonstrated a pooled relative risk (RR) of 1.43 (95% CI, 1.08–1.88); these grades increased to 1.63 (95% CI, 1.14–2.23) with the inclusion of studies only with high-quality GRADE criteria scores.

➢ High heterogeneity of the data originated in mutually analyzed. Although this evidence supports an association of hypomagnesemia with PPI use, it is unclear if this was associated with increased morbidity.[7]

✓ Disadvantages of Long-term Proton Pump Inhibitors:

- Use All clinical drugs to have both healing and adverse effects, with PPIs. Since the basic chemical structure of existing PPIs is similar, the adverse effects of the drugs are also like and can be divided into 2 types, those related and unrelated to acid inhibition.

- The majority of acid inhibition-related adverse effects are observed during long-term treatment with a PPI, while those unrelated to acid inhibition are observed in patients with long-term as well as those with short-term treatment.[8]

✓ Advantages of Long-term Proton Pump Inhibitor:

- PPIs potently prevent gastric acid secretion, especially throughout the day resulting in a daily single morning dose.

- PPIs are reported to be operative to prevent recurrence of reflux signs and esophageal erosions/ulcers.

- Long-term PPI admin is also helpful for preventing the reappearance of aspirin-induced gastroduodenal ulcers and is more effective than H2RAs, with a decrease in recurrence to around one-tenth of that seen in placebo-treated groups.

- Long-term conservation therapy with a PPI is active for preventing recurrence of GERD and may also prevent the neoplastic progression of Barrett's esophagus[9].

Adverse Actions Stated in Patients Preserved With Proton Pump Inhibitors[10-16]

Adverse events unrelated to acid inhibitors	Adverse events related to acid inhibition
Drug interaction	Pneumonia
Chronic kidney sickness	Gastrointestinal infection
Allergic reaction to drug chemical	Gastric carcinoid tumor
Dementia	Bone fracture
Collagenous colitis	Vitamin B12 deficiency
Cerebral ischemic illnesses	Colon cancer [48]

Current symptoms of proton pump inhibitor (PPI) medication

Clinical setting	PPI dose and extent
Erosive Esophagitis	Standard dose PPI therapy for 8-12 weeks
Non-H. pylori-related PU disease	Standard dose PPI therapy for 4-8 weeks
Treatment of gastro-duodenal lesions	Standard dose PPI therapy for 8 weeks [22]

Long-term consumption of PPIs and the hazard:

- The risk of pneumonia.
- The risk of dementia.
- The risk of kidney disease.
- The risk hypomagnesemia.
- Spontaneous bacterial peritonitis [31]

Proton Pumping Mechanism of the Gastric H^+, K^+-ATPase

The H+, K+-ATPase interactions intracellular hydrogen ions for extracellular ATP concentration. However, the stoichiometry of H+ per ATP was dissimilar dependent on the luminal pH. The H+ for K+ stoichiometry of the H+, K+-ATPase per ATP hydrolyzed was 1 at low pH, and 2 at neutral pH or near-neutral pH. The H+, K+-ATPase has numerous reaction stages for pumping the proton. The H+, K+-ATPase fixes the hydronium ion on the cytoplasmic side at high affinity, which is called E1 conformation. The primary step is the reversible binding of ATP to the enzyme in the nonappearance of added K+ ion, surveyed by an Mg2+ (and hydronium) dependent transmission of γ-phosphate of ATP to Asp386 of the catalytic subunit (E1-P·H+). Following phosphorylation, the conformation deviations from E1P·H3O+ to the E2P·H3O+ form, which has a high affinity for K+ and low affinity for H3O+, agreeing release of H3O+ and binding of K+ from the extra-cytoplasmic surface of the enzyme. The collapse of the E2P form requires K+ or its congeners on the outside face of the enzyme. With dephosphorylation, the E1K+ confirmation is made with a low affinity for K+, releasing K+ to the cytoplasmic side and

agreeing on the rebinding of H3O+. The adding of K+ to the enzyme-bound acyl phosphate marks in biphasic dephosphorylation. The faster initial step is reliant on the concentration of K^+, whereas the deliberate step is not affected by K+ concentration. The second phase of phosphoenzyme breaking is accelerated in the presence of K+ but, at K+ concentrations above 500 μM, the rate becomes independent of K+ concentration. This shows that 2 forms of phosphoenzyme exist. The first form, presumably E1P is K+ unmoved and converts freely in the rate-limiting step to E2P, the K+ sensitive form. ATP binding to the H+, K+-ATPase follows in both the E1 and the E2 state, but with a lower affinity in E2 state. The Mg2+ remains obstructed in the P domain near Asp73018 until dephosphorylation indifference to the Na+, K+-ATPase where the Mg ion is unrestricted from E 2P.[20]



Pharmacokinetic Properties of Proton Pump Inhibitors[32]

Properties	Omeprazole	Esomeprazole	Lansoprazole	Dexlansoprazole	Pantoprazole	Rabeprazole
Bioavailability	30-40	64-90	80-85	-	77	52
Time to peak plasma level(tmax, hr)	0.5-3.5	1.5	1.7	1-2,4-5	2-3	2-5
Protein binding	95	97	97	96	98	96.3
Half-life, hr	0.5-1	1-1.5	1.6	1-2	1-1.9	1-2
Primary excretion	Hepatic	Hepatic	Hepatic	Hepatic	Hepatic	Hepatic
Liver metabolism	CYP2C19	CYP2C19	CYP2C19	CYP2C19 CYP3A4	CYP2C19 CYP3A4	CYP2C19

Methods

1) Delayed-release tablets:

Center Tablets Rabeprazole sodium postponed discharge center tablets were set up by direct pressure procedure utilizing diverse excipients are utilized. H2 receptor, Sodium Carbonate anhydrous, Mannitol, and Crospovidone went through individual strainer no cand blend for separate mins. Sodium Stearyl Fumarate filtered and added to the readied mix. The powder mix was greased up with magnesium stearate and powder. Pack the greased up mix into tablets. [33]

2) Enteric Coating tablets:

Scatter Ethylcellulose in got dried out ethanol under mixing to get ready clear arrangement include Water insoluble polymer and blend well. Separation the center tablets into 2 equivalent parts and coat tablets in a covering machine with ethyl cellulose scattering to accomplish an objective weight addition of individual w/w and required w/w each. Warm the Seal-covered tablets in covering dish at required °C for separate mins. Scatter HPMC phthalate (HPMCP-55) in a blend of getting dried out ethanol and filtered water under mixing to plan clear arrangement. Add diacetylated monoglycerides to the readied arrangement. Get ready scattering of shade mix yellow with refined water utilizing homogenizer and add to the

above arrangement and blend well. Coat the seal covered tablets in a covering machine with covering answer for accomplishing an objective weight increase of required w/w. Warm the enteric-covered tablets in covering dish at explicit °C for individual mins. The formulations (tablets or capsules) will be prepared using conventional methods with modifications. Effervescence type floating systems of suitable proton pump inhibitors will be developed and suitably modified to adjust the drug release rate. The prepared formulations will be evaluated for hardness, weight variation, friability, drug content, buoyancy, and drug release rate using standard procedures.[34]

(3) Direct compression:

The enteric covered tablets were set up by direct pressure strategy. The gauged amount of required drug, mannitol, Sodium Carbonate Anhydrousand Hydroxypropyl cellulose was sieved through30 # size. The above-moved materials were greased up with crospovidone, powder, and Magnesium stearate for required minutes octagonal blender. These mixed materials were additionally exposed to pressure.[38]

Pre-compression studies:

a) Bulk Density (Db)

It is the ratio of the total mass of powder to the bulk volume of powder. It was measured by hammering the weight powder passed through a sieve into a measuring cylinder and initial weight was noted. This original volume is called the bulk volume. From this, the bulk density is calculated according to the formula mentioned below. It is expressed in g/ml and is given by,

$$Db = M/ Vb$$

Where,

M is the mass of powder

Vb is the bulk volume of the powder.[39]

b) Tapped Density (Dt)

It is the ratio of the total mass of the powder to the tapped volume of the powder. Volume was measured by tapping the powder for required times and the tapped volume was noted if the difference between these two volumes is less than 2%. If it is more than 2%, tapping is continued for times and tapped volume was noted. Tapping was continued until the difference between successive volumes is less than 2 % (in a bulk density apparatus). It is expressed in g/ml and is given by,

$$Dt = M / Vt$$

Where,

M is the mass of powder

Vt is the tapped volume of the powder.

c) The angle of Repose (Ɵ)

The friction forces in a loose powder can be measured by the angle of repose (q). It is indicative of the flow properties of the powder. It is defined as the maximum angle possible between the surface of the pile of powder and the horizontal plane. The flow Properties and Corresponding Angles of Repose.

$$\tan(Ɵ) = h / RI.eƟ = \tan\text{-}1\ (h / r)$$

Where,

Ɵ is the angle of repose.

h is the height in cm, r is the radius in cm.

Carr's index (or) % compressibility

It indicates powder flow properties. It is expressed in percentage and is given by,

$$I=Dt - Db / Dt\times100$$

Where,

Dt is the tapped density of the powder

Db is the bulk density of the powder.

Post-compression Studies

a) Weight variation test

Individual weights of 20 tablets were taken and the average weight was calculated by using the following formula. Weight variation specification as per IP/BP and USP are given. The weight variation specification as per IP/BP and USP.

$$\text{Weight variation} = \frac{\text{(Weight of tablet-Average weight)}}{\text{The average weight of the table}} \times 100$$

b) Hardness

The hardness of the tablets was observed by the use of hardness tester. Desired hardness was 6-8Kg/ in^2.

c) Thickness

The thickness of the tablets was calculated by the use of vernier calipers. Desired thickness was calculated.

d) Friability

Friability of the tablets was calculated by the use of a friabilator. Friability should be less than 1.

e) Disintegration time

Disintegration time of the tablet was observed with the help of disintegration test apparatus.[40]

SUMMARY

Overall, PPIs are irreplaceable drugs in the management of acid-related diseases. However, PPI treatment – as any kind of drug therapy – is not without risk of adverse effects. The overall benefits of therapy and improvement in the quality of life significantly outweigh

potential risks in most patients, but those without clear clinical indication are only exposed to the risks of PPI prescription. Adhering to evidence-based guidelines represents the only rational approach to an effective and safe PPI therapy.[45]

REFERENCES

1) El-Fatatry HM, Mabrouk MM, Hewala II, Emam EH. Stability-indicating HPLC–DAD methods for determination of two binary mixtures: Rabeprazole sodium–mosapride citrate and rabeprazole sodium–itopride hydrochloride. Journal of pharmaceutical analysis. 2014 Aug 1;4(4):258-69.

2) Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Therapeutic advances in drug safety. 2019 Jan;10:2042098618809927.

3) Brisebois S, Merati A, Giliberto JP. Proton pump inhibitors: Review of reported risks and controversies. Laryngoscope Investigative Otolaryngology. 2018 Dec;3(6):457-62

4) Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Therapeutic advances in drug safety. 2019 Jan;10:2042098618809927.

5) Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut and liver. 2017 Jan;11(1):27.

6) Babu SG, Kumar VD, Jyothi C, Malathy PS, Ramana H. Development and in vitro evaluation of delayed released tablets of rabeprazole sodium. Int J Pharm Res Biomed Anal. 2014;3(3):11-21.

7) Ansel HC, Allen LV, Popovich NG. Pharmaceutical dosage forms and drug delivery systems. Philadelphia, Lippincott Williams and Wilkins chapter-3, 2003:23-31.

8) Mayavanshi AV, Gajar SS. Floating drug delivery system to increase gastric retention of the drug: A Review J Pharm Res Oct-dec. 2008: 1940:345-348.

9) Chein YW. Novel Drug Delivery Systems. 2nd ed. New York: Marcel Dekker. Inc; 1992. pp. 1–139.

10) Santoskar RS, Rege NN, Bhandarkar SD. Pharmacology and Pharmacotherapeutics. 22nd. Mumbai: Popular Prakashan Pvt. Ltd;2011.pp.621-2

11) Khan MA, Kumar H, Kumar A, Ahmad KJ, Ahmad B. Preparation and evaluation of retention time of floating drug of Pantoprazole. Int J Curr Pharmaceut Res 2014; vol6(3):26-31.

12) Sarangapani S, Bangaru J, Rajappan M. In vitro and in vivo evaluation of the gastroretentive floating dosage form. Int Res J Pharm 2014; 5(9):695-700.

13) De A, Gill AK. Design, development, and in-vitro evaluation of floating bilayer tablets of Domperidone and Rabeprazole for the treatment of gastroesophageal reflux disorder. Int J Pharmaceut Chem Sci 2013; 2(2):909-17.

14) Senthilkumar SK, Jaykar B, Kavimani S. Formulation and evaluation gastro retentive floating drug delivery system of Rabeprazole sodium. Int J Biopharm 2011;2(2):57.

15) Sugar R, Masareddy R, Roopesh k. Hydrodynamically balanced tablets of Clarithromycin: an approach to prolong and increase the local action by gastric retention. Res J Pharmaceut Bio Chem 2010; 1(3):284-95.

16) Pahwa R, Jindal S, Chhabra L, Dutt H, Rao R. Development and in-vitro characterization of effervescent floating drug delivery system of Famotidine. Int J Pharmaceut Sci Res 2012; 3(1):241-6.

17) Rao GK, Mandapalli PK, Manthri R, Reddy VP. Development and in vivo evaluation of gastroretentive delivery system for Cefuroxime axetil. Saudi Pharmaceut J 2013; 21:53-9

18) Rathi SR, Patil VR, Patel MM, Patil AB, Shankhpal GA, Barhate SD. Formulation and evaluation of matrix floating tablet of Famotidine. J Pharm Res 2009;2(3):531-3.

19) Yeole PG, Khan S, Patel VF. Floating drug delivery systems need and development. Ind J Pharmaceut Sci 2005; 67(3):265-72.

20) Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription

21) Drug use among adults in the United States from 1999–2012.JAMA 2015;314:1818–1831.

22) Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr GastroenterolRep 2008;10:528–534.

23) Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006;23(Suppl 2):2–8.

24) Vaezi MF. Sensitivity and specificity of reflux-attributed laryngeal lesions: experimental and clinical evidence. Am J Med 2003;115:97–104.
25) Milstein CF, Charbel S, Hicks DM, Abelson TI, Richter JE, Vaezi MF. Prevalence of laryngeal irritation signs associated with reflux in asymptomatic.
26) volunteers: impact of endoscopic technique (rigid vs. flexible laryngoscope) Laryngoscope 2005;115:2256–2261.
27) Hicks DM, Ours TM, Abelson TI, Vaezi MF, Richter JE. The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers. J Voice 2002;16:564–579.
28) Fritz MA, Persky MJ, Fang Y, et al. The accuracy of the laryngopharyngeal reflux diagnosis: utility of the stroboscopic exam. Otolaryngol Head Nec Surg 2016;155:629–634.
29) Freedberg DE, Haynes K, Denburg MR, et al. Use of proton pump inhibitor is associated with fractures in young adults: a population-based study Osteoporos Int 2015;26:2501–2507.
30) Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, health individuals: a randomized, crossover, controlled clinical trial. J Bonein Miner Res 2010;25:2205–2211.
31) Targownik LE, Goertzen AL, Luo Y, Leslie WD. Long-term proton pump inhibitor use is not associated with changes in bone strength and structure Am J Gastroenterol 2017;112:95–101.
32) Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254–1259.
33) Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16(Suppl 2): S3–S7.
34) Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int 2016;27:339–347.
35) Targownik LE, Leslie WD, Davison KS, et al. The relationship between proto pump inhibitor use and longitudinal change in bone mineral density:
36) A population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012;107:1361–1369.
37) Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss Gastroenterology 2010;138:896–904.
38) Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008;83:251–259.
39) Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results fro the Women's Health Initiative. Arch Intern Med 2010;170:765–771.
40) Solomon DH, Diem SJ, Ruppert K, et al. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: SWAN cohort study. J Bone Miner Res 2015;30:232–239.
41) Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 2017;152:706–715.
42) Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review.
43) Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomized double blind study. Gut 1996;39:54–59.
44) Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011;34(11–12):1269–1281.
45) Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007;5:1418–1423.